Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Randomized, Controlled Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of HMPL-760 Plus R-GemOx Versus Placebo Plus R-GemOx in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma(R/R DLBCL)

NCT06601504 is registered in ClinicalTrials.gov with Hutchmed as lead sponsor.

NCT NCT06601504
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06601504 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Randomized, Controlled Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of HMPL-760 Plus R-GemOx Versus Placebo Plus R-GemOx in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma(R/R DLBCL)
Lead sponsor
Hutchmed
Phase
Phase 2
Overall status
Completed
Start date
November 5, 2024
Completion date
May 23, 2026
Enrollment
61 (actual)
Sites
16

Conditions

As the registry lists them; a condition with its own page is linked.

relapsed/refractory diffuse large b-cell lymphoma